ClinicalTrials.gg
RecruitingNCT05803395Updated Nov 28, 2023

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

An observational study in Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma and COVID-19, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. Recruiting at 15 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
954
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto — 5 open to participants now, 7 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Gruppo Italiano Malattie EMatologiche dell'Adulto.

Planned enrollment
2nd of 10
954 · median 203
Started
2023
with 2 others
Observational
10 of 18
3 open now
Registered
16th of 18
by date

Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto, this one is the 2nd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2023, is one of 10 observational ones, and was the 16th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

5 of the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gruppo Italiano Malattie EMatologiche dell'Adulto, or all of them as a file.
02

Study summary

This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients who received first COVID-19 prophylaxis dose between March 2022 and October 2022.

Read the detailed description

This is an observational retrospective and prospective multicenter study aimed at describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL or indolent B-NHL patients.

All CLL or indolent B-cell NHL patients (follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma) who received first COVID-19 prophylaxis dose with Tixagevimab and Cilgavimab according to AIFA indication between March 2022 and October 2022 will be included in the study.

Each patient will be followed for a maximum of 12 months from the first COVID-19 prophylaxis dose.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with CLL or indolent B-NHL (follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma) who received the Tixagevimab and Cilgavimab as per Agenzia Italiana del Farmaco (AIFA) indications.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Patient with CLL or indolent B-NHL who received the first COVID-19 prophylaxis dose with Tixagevimab and Cilgavimab as per label indication between March 2022 and October 2022.
  3. Signed , if applicable

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
954 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Assess the percentage of patients who develop severe COVID-19 infection

    Evaluation of prophylaxis efficacy in terms of percentage of patients with CLL or indolent B-NHL who develop severe COVID-19 infection, defined as COVID-19-related hospitalization or COVID -19 related death

    Time frame: at 12 months

07

Study locations

15 of 15 sites recruiting
  • UOC Ematologia AO Cosenza
    Cosenza, Italy
    Recruiting
    • Massimo Gentile · Contact
  • Ematologia AOU S.Anna
    Ferrara, Italy
    Recruiting
    • Antonio Cuneo · Contact
  • Ematologia AOU Careggi
    Firenze, Italy
    Recruiting
    • Alessandro Sanna · Contact
  • ASST Lecco Ospedale A.Manzoni
    Lecco, Italy
    Recruiting
    • Clara V Viganò · Contact
  • UOC Ematologia ATMO
    Livorno, Italy
    Recruiting
    • Rossella Riccioni · Contact
  • ASST Grande Ospedale Metropolitano Niguarda
    Milano, Italy
    Recruiting
    • Anna Maria Frustaci · Contact
  • SCDU Ematologia
    Novara, Italy
    Recruiting
    • Riccardo Moia · Contact
  • Dipartimento Oncologico La Maddalena
    Palermo, Italy
    Recruiting
    • Maurizio Musso · Contact
  • UOC DI ONCOEMATOLOGIA AOR Villa Sofia - Cervello
    Palermo, Italy
    Recruiting
    • Caterina Patti · Contact
  • Ematologia Università "Sapienza" Roma
    Roma, Italy
    Recruiting
    • Francesca R Mauro · Contact
  • IRCCS Istituto Clinico Humanitas
    Rozzano, Italy
    Recruiting
    • Armando Santoro · Contact
  • UOC Ematologia Casa Sollievo della Sofferenza
    San Giovanni Rotondo, Italy
    Recruiting
    • Angelo Carella · Contact
  • SCDU Ematologia e terapie cellulari AO Mauriziano
    Torino, Italy
    Recruiting
    • Daniela Gottardi · Contact
  • Ematologia Ospedale S.Chiara
    Trento, Italy
    Recruiting
    • Anna Guella · Contact
  • UOC ematologia ULSS2 Marca Trevigiana
    Treviso, Italy
    Recruiting
    • Filippo Gherlinzoni · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2024, 12 months after the start.

Of 70 non-industry observational studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30. This study's planned 12 months is below that.

Counting every sponsor, half of 104 studies reached it within 60 months; a quarter within 31 and three quarters within 176.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2023
First posted
Apr 7, 2023
StartActual
Sep 12, 2023
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2024
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05803395
Collaborators
Fondazione Italiana Linfomi
Responsible party
Sponsor
First posted
Apr 7, 2023
Start date
Sep 12, 2023
Primary completion
Sep 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Nov 28, 2023

Study contacts

Paola Fazi
Contact
p.fazi@gimema.it
0670390528
Enrico Crea
Contact
e.crea@gimema.it
0670390514
Gian Matteo Rigolin
principal investigator · Ematologia - Azienda Ospedaliero Universitaria S.Anna di Ferrara

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion